Rolph Timothy 的 Form 4/A 修正申報
修正Akero Therapeutics, Inc.（AKRO），2022/10/27 申報
- 申報編號
- 0000899243-22-034368
- 申報時間
- 2022/10/27
- 交易日
- 2022/9/13
- 申報延遲
- 44 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2022/9/15
這份申報列了 2 筆非衍生性交易、1 筆衍生性交易。公開市場賣出合計 $65.7 萬。交易後 44 天申報。
這份修正申報取代了 0000899243-22-031196（2022/9/15 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Rolph TimothyCIK 0001779479 | 高階主管（科學長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2022/9/13 | Common Stock | M行使選擇權取得 | +10,000 | $6.36 | +$63,600 | 256,337 | 直接 | |
| 2022/9/13 | Common Stock | S賣出處分 | −22,500 | $29.18F3 | −$656,550 | 233,837 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2022/9/13 | Common Stock | M行使選擇權處分 | −10,000 | $0.00 | $0 | 62,756 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
On September 15, 2022, the reporting person filed a Form 4 which inadvertently omitted the exercise of 10,000 options by the reporting person. The shares of Common Stock underlying those options were subsequently sold pursuant to a Rule 10b5-1 trading plan as reported in the original Form 4. This amendment to the original Form 4 is being filed solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock.
- F2
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 25, 2021, previously adopted by the reporting person.
- F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
- F4
This option shall vest and become exercisable in 48 equal monthly installments, commencing on January 1, 2019.